home · filing · 0001104659-21-122499
8-K filed October 4, 2021, 7:59 PM ET
ticker NXTC
CIK 0001661059
leadership
confidence high
sentiment neutral
materiality 0.50
NextCure appoints Anne Borgman, M.D., and Ellen Feigal, M.D. to board
NextCure, Inc.
Borgman joins as Class I director; Feigal as Class II director; both deemed independent.
Borgman serves on Nominating and Governance Committee; Feigal on Compensation Committee.
Borgman is VP at Jazz Pharmaceuticals; Feigal is Partner at NDA Partners.
Appointments follow resignation of Stella Xu, Ph.D. from the board.
New directors bring oncology and biopharma development expertise.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Ellen Feigal, M.D.
Director
Effective 2021-10-01
Filed October 4, 2021, 7:59 PM ET
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
Appointed
Anne Borgman, M.D.
Director
Effective 2021-10-01
Filed October 4, 2021, 7:59 PM ET
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Ellen Feigal, M.D. was elected as Director at NextCure, Inc..
Action elected
Role Director
Exact text from the filing
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Anne Borgman, M.D. was elected as Director at NextCure, Inc..
Action elected
Role Director
Exact text from the filing
elected Anne Borgman, M.D., and Ellen Feigal, M.D., to the Board.
View on SEC.gov
Source: SEC EDGAR
accession 0001104659-21-122499
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.